A case report of refractory canine atopic dermatitis successfully treated with adipose-derived mesenchymal stem cells

Abstract

We treated canine atopic dermatitis that had failed to respond to existing treatments with allogeneic adipose-derived mesenchymal stem cells (Ad-MSCs) for the first time in Japan in anticipation of their immunomodulating and anti-inflammatory effects. Improvement of symptoms was observed within approximately one month, and the dosage of prednisolone and cyclosporine was reduced to less than half of the initial dosage during the observation period of approximately eight months, with no worsening of symptoms. No adverse events were observed during the observation period. The results suggest that Ad-MSCs may be a safe and effective treatment option for refractory canine atopic dermatitis.